Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 / 抗感染 / Antiparasitic / Fexinidazole

非昔硝唑 /Fexinidazole {[allProObj[0].p_purity_real_show]}

货号：A322155 同义名： HOE 239;Fexinidazole Winthrop

Fexinidazole is a 5-nitroimidazole drug for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei.

Fexinidazole 化学结构 CAS号：59729-37-2
Fexinidazole 化学结构
CAS号：59729-37-2
Fexinidazole 3D分子结构
CAS号：59729-37-2
Fexinidazole 化学结构 CAS号：59729-37-2
Fexinidazole 3D分子结构 CAS号：59729-37-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Fexinidazole 纯度/质量文件 产品仅供科研

货号：A322155 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

Fexinidazole 生物活性

靶点

  • DNA synthesis
描述 Human African Trypanosomiasis (HAT), or sleeping sickness, is a life-threatening, neglected tropical disease (NTD). The etiological agent of HAT is the kinetoplastid protozoan parasite Trypanosoma brucei (T. b.). Two subspecies of this parasite are pathogenic for humans: T. b. gambiense (g-HAT) responsible for the chronic form of the disease occurring in western and central Africa, and T. b. rhodesiense (r-HAT) responsible for a more acute form occurring in eastern and southern Africa. Fexinidazole, a 5-nitroimidazole derivative DNA synthesis inhibitor, is the only, all-oral treatment for HAT and is indicated for use by adults and children (aged ≥ 6 years and weighing ≥ 20 kg) for both g-HAT stages[3]. This molecule and its metabolites (sulfoxide and sulfone) have shown trypanocidal activity in vitro in the 0.7-to-3.3 μM (0.2-to-0.9 μg/ml) range against all parasite strains tested. In vivo, fexinidazole is orally effective in curing both acute and chronic diseases in the mouse at doses of 100 mg/kg of body weight/day for 4 days and 200 mg/kg/day for 5 days, respectively[4].

Fexinidazole 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02571062 Trypanosomiasis, African Phase 1 Completed - France ... 展开 >> Biotrial Rennes, France 收起 <<
NCT02498782 Chagas Disease ... 展开 >> Trypanosomiasis, South American South American Trypanosomiasis Disease, Chagas 收起 << Phase 2 Unknown February 2016 Bolivia ... 展开 >> Plataforma Atención Integral de Pacientes con Enfermedad de Chagas Recruiting Cochabamba, Bolivia Contact: Faustino Torrico, MD    59177411905    foxtorrico@yahoo.com    Contact: Cristina Alonso, MD    59172211312    calonso@dndi.org    Principal Investigator: Faustino Torrico, MD          Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas Recruiting Tarija, Bolivia Contact: Lourdes O Daza, MD    5916672252    lourdesortizd@yahoo.es    Contact: Erika Ribeiro, Pharm D    59175969924    ecorreia@dndi.org    Principal Investigator: Lourdes O Daza, MD 收起 <<
NCT01483170 Trypanosomiasis, African Phase 1 Terminated(poor tolerability a... 展开 >>t highest dose) 收起 << - France ... 展开 >> SGS Life Sciences Paris, France, 75015 收起 <<

Fexinidazole 参考文献

[1]Kaiser M, Bray MA, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8.

[2]Torreele E, Bourdin Trunz B, et al. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.

[3]Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole

[4]Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping Sickness

Fexinidazole 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.58mL

0.72mL

0.36mL

17.90mL

3.58mL

1.79mL

35.80mL

7.16mL

3.58mL

Fexinidazole 技术信息

CAS号59729-37-2
分子式C12H13N3O3S
分子量 279.315
别名 HOE 239;Fexinidazole Winthrop
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Room Temperature
溶解度

DMSO: 50 mg/mL(179.01 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

Tags: Fexinidazole | HOE 239;Fexinidazole Winthrop | Antiparasitic | AmBeed-信号通路专用抑制剂 | Fexinidazole 纯度/质量文件 | Fexinidazole 生物活性 | Fexinidazole 临床数据 | Fexinidazole 参考文献 | Fexinidazole 实验方案 | Fexinidazole 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z